 Nick Levinsky
Concepts (133)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Glycoproteins | 2 | 2020 | 359 | 0.680 |
Why?
| | Reperfusion Injury | 2 | 2021 | 287 | 0.670 |
Why?
| | Chemoradiotherapy, Adjuvant | 2 | 2019 | 43 | 0.660 |
Why?
| | Intestines | 2 | 2021 | 358 | 0.640 |
Why?
| | Neoadjuvant Therapy | 2 | 2019 | 409 | 0.620 |
Why?
| | Carcinoma, Signet Ring Cell | 1 | 2019 | 17 | 0.620 |
Why?
| | Appendiceal Neoplasms | 1 | 2019 | 29 | 0.620 |
Why?
| | Cytoreduction Surgical Procedures | 1 | 2019 | 62 | 0.600 |
Why?
| | Prescription Drugs | 1 | 2020 | 115 | 0.600 |
Why?
| | Esophagectomy | 1 | 2019 | 132 | 0.570 |
Why?
| | Neutrophils | 3 | 2021 | 1280 | 0.550 |
Why?
| | Time-to-Treatment | 1 | 2019 | 209 | 0.550 |
Why?
| | Esophageal Neoplasms | 1 | 2019 | 322 | 0.480 |
Why?
| | Opioid-Related Disorders | 1 | 2020 | 541 | 0.390 |
Why?
| | Adenocarcinoma | 1 | 2019 | 882 | 0.380 |
Why?
| | Pancreatectomy | 3 | 2017 | 241 | 0.310 |
Why?
| | Pancreaticoduodenectomy | 4 | 2017 | 127 | 0.280 |
Why?
| | Lung Neoplasms | 1 | 2020 | 2531 | 0.270 |
Why?
| | Pain, Postoperative | 2 | 2020 | 298 | 0.260 |
Why?
| | Salvage Therapy | 2 | 2019 | 152 | 0.250 |
Why?
| | Pancreatitis, Chronic | 2 | 2016 | 59 | 0.230 |
Why?
| | Databases, Factual | 2 | 2019 | 1399 | 0.210 |
Why?
| | Retrospective Studies | 9 | 2020 | 15860 | 0.190 |
Why?
| | Mesenteric Ischemia | 1 | 2021 | 2 | 0.180 |
Why?
| | Analgesics, Opioid | 2 | 2020 | 1076 | 0.180 |
Why?
| | Pneumonia, Ventilator-Associated | 1 | 2021 | 54 | 0.170 |
Why?
| | Granulocyte Colony-Stimulating Factor | 1 | 2021 | 88 | 0.170 |
Why?
| | AMP-Activated Protein Kinases | 1 | 2021 | 201 | 0.160 |
Why?
| | Survival Rate | 3 | 2019 | 1932 | 0.160 |
Why?
| | Colorectal Surgery | 1 | 2019 | 25 | 0.160 |
Why?
| | Nitric Oxide Synthase Type II | 1 | 2019 | 174 | 0.150 |
Why?
| | Shock, Hemorrhagic | 1 | 2021 | 170 | 0.150 |
Why?
| | Peritoneal Neoplasms | 1 | 2019 | 98 | 0.150 |
Why?
| | Anti-Infective Agents | 1 | 2021 | 238 | 0.150 |
Why?
| | Mice, Knockout | 3 | 2021 | 3038 | 0.150 |
Why?
| | Pancreatic Neoplasms | 2 | 2017 | 856 | 0.140 |
Why?
| | Acute Lung Injury | 1 | 2021 | 299 | 0.140 |
Why?
| | Elective Surgical Procedures | 1 | 2019 | 190 | 0.140 |
Why?
| | Up-Regulation | 1 | 2021 | 851 | 0.140 |
Why?
| | Jejunostomy | 1 | 2017 | 13 | 0.130 |
Why?
| | Pancreatitis, Acute Necrotizing | 1 | 2017 | 14 | 0.130 |
Why?
| | Sepsis | 2 | 2021 | 606 | 0.130 |
Why?
| | Aged | 8 | 2019 | 24182 | 0.130 |
Why?
| | Reoperation | 2 | 2016 | 585 | 0.130 |
Why?
| | Middle Aged | 10 | 2021 | 33792 | 0.120 |
Why?
| | Common Bile Duct Neoplasms | 1 | 2016 | 23 | 0.120 |
Why?
| | Duodenal Neoplasms | 1 | 2016 | 24 | 0.120 |
Why?
| | Ampulla of Vater | 1 | 2016 | 34 | 0.120 |
Why?
| | Prognosis | 3 | 2019 | 4015 | 0.120 |
Why?
| | NF-kappa B | 1 | 2019 | 679 | 0.120 |
Why?
| | Male | 12 | 2021 | 68216 | 0.120 |
Why?
| | Mice, Inbred C57BL | 3 | 2021 | 5812 | 0.110 |
Why?
| | Islets of Langerhans Transplantation | 1 | 2015 | 65 | 0.110 |
Why?
| | Female | 12 | 2021 | 73913 | 0.110 |
Why?
| | Cause of Death | 1 | 2016 | 425 | 0.110 |
Why?
| | Length of Stay | 1 | 2019 | 1229 | 0.100 |
Why?
| | Treatment Outcome | 5 | 2019 | 10938 | 0.100 |
Why?
| | Combined Modality Therapy | 1 | 2016 | 1237 | 0.100 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 2 | 2019 | 1748 | 0.100 |
Why?
| | Carcinoma, Pancreatic Ductal | 1 | 2016 | 266 | 0.100 |
Why?
| | Acute Kidney Injury | 1 | 2020 | 811 | 0.090 |
Why?
| | United States | 2 | 2019 | 15018 | 0.090 |
Why?
| | Colorectal Neoplasms | 1 | 2019 | 803 | 0.090 |
Why?
| | Time Factors | 2 | 2019 | 6877 | 0.090 |
Why?
| | Mice | 4 | 2021 | 17848 | 0.080 |
Why?
| | Apoptosis | 1 | 2019 | 2558 | 0.080 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2016 | 1065 | 0.080 |
Why?
| | Appendectomy | 1 | 2010 | 89 | 0.080 |
Why?
| | Humans | 11 | 2021 | 138651 | 0.080 |
Why?
| | Appendicitis | 1 | 2010 | 140 | 0.070 |
Why?
| | Postoperative Complications | 2 | 2017 | 2701 | 0.070 |
Why?
| | Animals | 5 | 2021 | 37309 | 0.070 |
Why?
| | Health Care Costs | 1 | 2010 | 418 | 0.060 |
Why?
| | Signal Transduction | 1 | 2019 | 5091 | 0.060 |
Why?
| | Risk Factors | 1 | 2019 | 10398 | 0.060 |
Why?
| | Cost-Benefit Analysis | 2 | 2019 | 605 | 0.050 |
Why?
| | Occludin | 1 | 2021 | 12 | 0.050 |
Why?
| | Glycocalyx | 1 | 2021 | 26 | 0.040 |
Why?
| | Cell Membrane Permeability | 1 | 2021 | 82 | 0.040 |
Why?
| | Disease Models, Animal | 2 | 2021 | 4333 | 0.040 |
Why?
| | Peroxidase | 1 | 2021 | 183 | 0.040 |
Why?
| | Hospitalization | 1 | 2010 | 2219 | 0.040 |
Why?
| | Cadherins | 1 | 2021 | 203 | 0.040 |
Why?
| | Tomography, X-Ray Computed | 1 | 2010 | 2703 | 0.040 |
Why?
| | Peritonitis | 1 | 2020 | 86 | 0.040 |
Why?
| | Preoperative Period | 1 | 2019 | 142 | 0.040 |
Why?
| | Intubation, Intratracheal | 1 | 2021 | 265 | 0.040 |
Why?
| | Age Factors | 2 | 2016 | 3274 | 0.040 |
Why?
| | Swine | 1 | 2021 | 802 | 0.040 |
Why?
| | Bone Marrow Transplantation | 1 | 2020 | 291 | 0.040 |
Why?
| | Statistics, Nonparametric | 1 | 2019 | 431 | 0.040 |
Why?
| | Risk Assessment | 2 | 2019 | 3459 | 0.040 |
Why?
| | Propensity Score | 1 | 2019 | 312 | 0.030 |
Why?
| | Organoplatinum Compounds | 1 | 2017 | 48 | 0.030 |
Why?
| | Pain Measurement | 1 | 2019 | 539 | 0.030 |
Why?
| | CA-19-9 Antigen | 1 | 2017 | 27 | 0.030 |
Why?
| | Erlotinib Hydrochloride | 1 | 2017 | 69 | 0.030 |
Why?
| | Leucovorin | 1 | 2017 | 85 | 0.030 |
Why?
| | Respiration, Artificial | 1 | 2021 | 667 | 0.030 |
Why?
| | Adult | 5 | 2021 | 38296 | 0.030 |
Why?
| | Anastomosis, Surgical | 1 | 2017 | 158 | 0.030 |
Why?
| | Blood Loss, Surgical | 1 | 2017 | 104 | 0.030 |
Why?
| | Albumins | 1 | 2017 | 116 | 0.030 |
Why?
| | Tertiary Care Centers | 1 | 2017 | 170 | 0.030 |
Why?
| | Endothelial Cells | 1 | 2021 | 792 | 0.030 |
Why?
| | Fluorouracil | 1 | 2017 | 204 | 0.030 |
Why?
| | Paclitaxel | 1 | 2017 | 237 | 0.030 |
Why?
| | Confidence Intervals | 1 | 2016 | 336 | 0.030 |
Why?
| | Deoxycytidine | 1 | 2017 | 193 | 0.030 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2017 | 377 | 0.030 |
Why?
| | Epithelial Cells | 1 | 2021 | 1102 | 0.030 |
Why?
| | Cohort Studies | 2 | 2019 | 5729 | 0.030 |
Why?
| | Pancreas | 1 | 2017 | 325 | 0.030 |
Why?
| | Transplantation, Autologous | 1 | 2015 | 276 | 0.030 |
Why?
| | Odds Ratio | 1 | 2016 | 1084 | 0.030 |
Why?
| | Clinical Decision-Making | 1 | 2016 | 332 | 0.030 |
Why?
| | Recurrence | 1 | 2016 | 1102 | 0.020 |
Why?
| | Cytokines | 1 | 2021 | 2084 | 0.020 |
Why?
| | Patient Selection | 1 | 2016 | 692 | 0.020 |
Why?
| | Genetic Predisposition to Disease | 1 | 2020 | 2368 | 0.020 |
Why?
| | Anti-Bacterial Agents | 1 | 2021 | 1810 | 0.020 |
Why?
| | Gene Expression Regulation | 1 | 2020 | 2602 | 0.020 |
Why?
| | Sex Factors | 1 | 2016 | 2058 | 0.020 |
Why?
| | Inflammation | 1 | 2021 | 2857 | 0.020 |
Why?
| | Prospective Studies | 1 | 2021 | 7639 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2016 | 2861 | 0.020 |
Why?
| | Lung | 1 | 2021 | 4086 | 0.020 |
Why?
| | Young Adult | 2 | 2015 | 13322 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2015 | 5160 | 0.020 |
Why?
| | Laparoscopy | 1 | 2010 | 448 | 0.010 |
Why?
| | Adolescent | 2 | 2015 | 21528 | 0.010 |
Why?
| | Aged, 80 and over | 1 | 2015 | 7683 | 0.010 |
Why?
| | Emergency Service, Hospital | 1 | 2010 | 2103 | 0.010 |
Why?
|
|
Levinsky's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|